Immunophotonics’ CIO, Tomas Hode, PhD, is attending the Spectrum Conference, January 15–17, in Miami, Florida.

This event brings together some of the most talented minds in interventional oncology, and Tomas looks forward to connecting, sharing ideas, and learning about the latest advancements in interventional therapeutics. These insights will help us advance clinical trials of IP-001, with the ultimate goal of making this innovative drug candidate available to patients in need as quickly as possible.